VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AD/PD 2022 | Investigating α-synuclein aggregation as a therapeutic target in Parkinson’s disease

Tim Bartels, PhD, University College London, London, UK, discusses ongoing investigations looking into how to target aggregation as a therapeutic strategy in Parkinson’s disease. Strategies to prevent aggregation of α-synuclein have not been particularly successful so far, as it is difficult to find specific binders that are efficient at low concentrations. One strategy focuses on targeting the aggregates with antibody therapies when they are moving between cells. Dr Bartel’s team are also looking at monomer-tetramer ratios in this setting: he suggests that having less monomers or stabilizing tetramers may be promising approaches. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.

Disclosures

Some research was funded by Eisai